Helium One Global (LON: HE1) launched a retail offer to existing shareholders late on Tuesday afternoon. It is raising up to £1m at 0.54p/share. The company has already raised £10m. This will fund working capital for the helium explorer. The share price rose 12.5% to 0.675p.
Automotive interior components manufacturer CT Automotive (LON: CTA) is on track to meet full year expectations. Interim revenues fell from $60.5m to $54.2m, but the second half should be stronger. New contracts worth a total of $37m annually have been won in the first half. This provides a strong base for growth over the next three years. The share price recovered 12.1% to 37p.
Metals Exploration (LON: MTL) has been granted an exploration licence over the Dupax project area in Northern Luzon, Philippines. IP surveying is underway. The share price increased 3% to 13.75p.
Leak detection services provider Water Intelligence (LON: WATR) has reacquired the franchisee for Georgia in the US. The initial payment is $350,000 in cash with additional payments based on profit. The share price improved 1.67% to 305p.
FALLERS
Drug developer ImmuPharma (LON: IMM) reported a reduction in loss from £2.78m to £1.95m in the six months to June 2025. The underlying improvement is masked by a loss on a derivative asset. Studies have helped to strengthen the commercial viability of the P140 technology platform and discussions continue with potential partners. The share price dived 25.5% to 1.55p.
There was profit-taking in SIMEC Atlantis Energy (LON: SAE) following yesterday’s announcement that it has reached financial close on the AW1 BESS project in South Wales. This is a 120MW generation project and construction has begun at Uskmouth. A global renewable energy partner is taking a 24.7% stake in the project. Zeus has increased the 2025 revenues forecast from £7.4m to £11.4m and the 2026 estimate from £7.5m to £12.5m. In each year the expected loss has been more than halved to around £3m. Net debt is expected to be £65.1m at the end of 2025 and rise to £99.9m one year later. The share price dipped 17.4% to 3.8p, but it is still double the 1.9p at the start of the week.
Media analysis business Ebiquity (LON: EBQ) says 2025 interim revenues were flat at £37.9m. North American, where economic uncertainty has hit client spending, revenues fell and that was offset by growth in the rest of the world. Operating profit is expected to improve from £2.3m to £2.6m. Net debt is slightly lower at £15m. North America remains a focus for the company despite the short-term problems. Trading is in line with expectations. The share price declined 13.3% to 19.5p.
Pharma mathematical modelling Physiomics (LON: PYC) has been awarded a second contract by a UK-based biotech, having completed the previous contract. The new model will support dosing strategy, and the contract is valued at £38,000. The share price fell 4.35% to 0.44p.